Agilent Technologies, Inc.

New York Stock Exchange
Back to all articles
Bullish +75

Agilent Technologies' Cancer Test Gets Expanded Approval From FDA

🏥 Agilent Technologies received FDA approval to expand its PD-L1 cancer test to four additional tumor types.

🔬 The expanded indications include esophageal squamous cell carcinoma, triple-negative breast cancer, cervical cancer, and gastric or gastroesophageal junction cancers.

💊 This testing helps identify patients eligible for treatment with Merck's Keytruda immunotherapy drug.

🤝 PD-L1 was originally developed by Agilent in partnership with Merck as a companion diagnostic for Keytruda.

🔄 The approval extends previous indications for non-small cell lung cancer and head and neck squamous cell carcinoma to the new Dako Omnis platform.

⚙️ Previously, those initial approved indications were only available on the Autostainer Link 48 platform.

🧬 Labs can now consolidate testing across more tumor types within a single Dako Omnis workflow.

📅 The FDA approval was announced on Tuesday by the laboratory technologies company.

Bullish Signals
  • Agilent Technologies received FDA approval to expand its PD-L1 cancer test to four additional tumor types, including esophageal squamous cell carcinoma, triple-negative breast cancer, cervical cancer, and gastric or gastroesophageal junction cancers.
  • The expanded approval enables the Dako Omnis platform to diagnose these new indications, allowing laboratories to consolidate testing across more tumor types within a single workflow.
  • This expansion builds upon previous FDA approvals for non-small cell lung cancer and head and neck squamous cell carcinoma on the Autostainer Link 48 platform, demonstrating sustained regulatory success.
  • The PD-L1 test serves as a companion diagnostic for Merck's Keytruda, facilitating patient identification for eligible treatments across a broader range of cancers.
Risk Factors
  • The approval is limited to four additional tumor types, excluding other potential indications that could have been pursued.
  • The test remains a companion diagnostic for Merck's Keytruda, meaning Agilent's revenue growth is contingent on the continued market success of Merck's drug rather than standalone demand.
Full Analysis
Agilent Technologies received FDA approval to expand the use of its PD-L1 testing technology, known as Dako Omnis, to four additional tumor types: esophageal squamous cell carcinoma, triple-negative breast cancer, cervical cancer, and gastric or gastroesophageal junction cancers. This expansion allows laboratories to consolidate testing across these new indications within a single workflow on the Dako Omnis platform, building upon previous approvals for non-small cell lung cancer and head and neck squamous cell carcinoma which were initially limited to the Autostainer Link 48 platform. The PD-L1 test serves as a companion diagnostic developed by Agilent in partnership with Merck to help identify patients eligible for treatment with Merck's Keytruda immunotherapy drug.